Marc Dechamps

COO

Delphi Genetics

Belgium

Professional Summary

Marc Dechamps is an accomplished, dedicated biologist and pharmaceutical executive serving as Chief Operating Officer of Delphi Genetics, a Belgian Biotech company. Marc manages the operations and particularly the commercial operations of the company, leading the effort to commercialize the bio-production of plasmid DNA, recombinant proteins and antibodies globally with or with or without the patented Staby technology allowing a production completely antibiotic free. He has extensive experience in market access and pricing for specialized therapeutics in Europe, general management of mid size operating companies in Europe (Belgium, The Netherlands, Portugal & Switzerland) strategy and operations in specialty care HIV, Onco - Hematology, CNS, rare disease & vaccines, and Management of multi-cultural/function people and teams. His areas of expertise are commercial operations, strategy, pharmaceutical sales and marketing, Biotech and Biology, leadership and management. Prior to his current position, Marc held several senior roles at GSK or in GSK companies, including Executive Director Commercial Specialty Care & Vaccines in Belgium, General Manager of a region of 4 Local operating companies at ViiVHealthcare and Head of Commercial, Market Access/Pricing & Policy/Patient advocacy operations at ViiV Healthcare Europe. These roles helped him develop diverse competencies and a deep knowledge of the Pharma and Biotech industries. Overall, he worked for 33 years with GlaxoSmithKline in Europe. Marc graduated with a Master of Science in Biology with Distinction from Facultés universitaires 'Notre-Dame de la Paix', Belgium, in 1981. He speaks fluent English, French and Flemish/Dutch. Originally, Marc was inspired to work in this field so that he'd be able to bring innovative meds to patients, especially for HIV patients. Indeed, he believes you can immediately feel what can bring to patients which is very inspiring. Going forward, Marc will be doing public speaking , focusing on the need to produce bio-products without antibiotics and antibiotics gene of resistance and having much more involvement in government and approaching audiences to whom these pharmaceuticals and absence of antibiotics in the development are important. In addition, Marc will soon step into the role of CEO for the company and wants to develop it into a leader in genetic engineering and bioproduction, with a core business in plasmid DNA development and applications, working with their partners mainly on human usage. The key to his success thus far has been his level of involvement, as Marc does everything to achieve success, and failure is not in his vocabulary. He puts all of his energy into achieving his goals with his team and in the company. He is keen to network with others in pharma and biotech and gain exposure for Delphi Genetics. Although there have been many achievements during Marc's career, one highlight was receiving the GSK European President's Award for Launch Excellence, Eddie Gray & Erik Van Snippenberg in December 2009. When he's not working, Marc enjoys mountain biking.

Skills

Specialization

Commercial Operations; Strategy; Pharmaceutical Industry; Corporate Coaching; Executive Office Management; Biology; Operational Management